详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

CD151 and prostate cancer progression: A review of current literature

58| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China [2]Lanzhou Univ, Sch Basic Med Sci, Dept Immunol, Lanzhou, Peoples R China [3]Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Peoples R China [4]Univ Hosp Cleveland Med Ctr, Dept Radiol, Cleveland, OH USA [5]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, 1095,Jiefang Ave, Wuhan 430030, Peoples R China

出处：

DOI：

ISSN：

关键词： CD151 prostate cancer tumor progression

摘要：

Prostate cancer morbidity and mortality are increasing globally and in China, and the rate of metastasis is also rising, limiting the therapeutic effect and clinical prognosis of prostate cancer. CD151 is considered to be the first promoter of tumor metastasis in the tetraspanin superfamily. Previous research has linked CD151 to the progression of a number of malignancies, including prostate cancer. However, a recent study found that CD151 can inhibit the progression of prostate cancer. As a result, this paper examines existing research on CD151 and prostate cancer progression in order to clarify the relationship and provide a possible reference for future studies.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2021]版：

Q4 ONCOLOGY

最新[2023]版：

Q4 ONCOLOGY

影响因子： 1.4 最新[2023版] 1.8 最新五年平均 1.926 出版当年[2021版] 2.286 出版当年五年平均 2.601 出版前一年[2020版] 1.9 出版后一年[2022版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China

通讯作者：

通讯机构： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China [5]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, 1095,Jiefang Ave, Wuhan 430030, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy [2]Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression [3]Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression [4]CXCL9: evidence and contradictions for its role in tumor progression [5]AutocrineINSL5 promotes tumor progression and glycolysis via activation ofSTAT5 signaling [6]Thrombospondin-1 is a multifaceted player in tumor progression [7]Roles of Microvesicles in Tumor Progression and Clinical Applications [8]Inhibition of KPNA4 attenuates prostate cancer metastasis [9]The Role of Calcium Channels in Prostate Cancer Progression and Potential as a Druggable Target for Prostate Cancer Treatment [10]AIF1 drives tumor progression via a cellular cross-talk with the tumor microenvironment